Table 3 Baseline 6MWT and MPS-HAQ results of individual patients
ID | Endurance | MPS-HAQ | ||
|---|---|---|---|---|
6MWT (m) | SC | MOB | CS | |
Founder pathogenic variant group | ||||
 1 | 27 | 3.1 | 6.6 | 22 |
 3 | 321 | 0.2 | 4.7 | 23 |
 7 | 138 | 0.7 | 6.3 | 26 |
 17 | NM | 2.4 | 5.7 | 14 |
 18 | 371 | NA | NA | NA |
 20 | 246 | 1.9 | 3.3 | 23 |
 21 | 330 | 1.2 | 2.2 | 23 |
 22 | NA | NA | NA | NA |
 24 | 230 | 1.2 | 5.7 | 13 |
 26 | 423 | 0.4 | 2.1 | 15 |
 27 | 338 | 0.04 | 1.6 | 14 |
 29 | 123 | 2.1 | 4.5 | 21 |
 30 | NM | 5.2 | 8.6 | 20 |
 31 | 535 | 1.5 | 2.5 | 13 |
 32 | NA | 0.8 | 2.7 | 13 |
 33 | NM | 0.3 | 5.6 | 33 |
 34 | 347 | NA | NA | NA |
Non-founder pathogenic variant group | ||||
 2 | NM | 8.8 | 9.8 | 47 |
 4 | 289 | 2.7 | 1.2 | 17 |
 5 | 458 | 1.5 | 0.9 | 19 |
 6 | 261 | NA | NA | NA |
 8 | 225 | NA | NA | NA |
 9 | NM | 9.5 | 10.0 | 51 |
 11 | NM | 9.2 | 10.0 | 52 |
 12 | NM | 2.9 | 8.3 | 42 |
 13 | 439 | 0.4 | 3.1 | 13 |
 14 | 141 | 4.4 | 8.0 | 37 |
 15 | NM | 7.6 | 10.0 | 48 |
 16 | 25 | 5.2 | 9.0 | 37 |
 19 | 171 | 3.2 | 5.6 | 36 |
 23 | NA | 4.1 | 1.5 | 30 |
 25 | 120 | 5.1 | 8.7 | 28 |
 28 | 36 | NA | NA | NA |